We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+6.22%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.54B
AUM Growth
+$215M
Cap. Flow
-$203M
Cap. Flow %
-2.69%
Top 10 Hldgs %
62.44%
Holding
434
New
139
Increased
87
Reduced
85
Closed
95

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$118M
2
INCY icon
Incyte
INCY
+$117M
3
GRFS
Grifois
GRFS
+$51.9M
4
HUM icon
Humana
HUM
+$47.4M
5
KO icon
Coca-Cola
KO
+$45.2M

Sector Composition

Rank Sector Weight
1 Healthcare 33.9%
2 Consumer Staples 5.54%
3 Consumer Discretionary 5.08%
4 Technology 3.55%
5 Communication Services 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WRBY icon
101
Warby Parker
WRBY
$3.16B
$10M 0.13%
+736,000
New +$9.77M
FL
102
DELISTED
Foot Locker
FL
$9.38M 0.12%
329,253
+11,679
+4% +$336K
TMO icon
103
Thermo Fisher Scientific
TMO
$213B
$8.7M 0.12%
+14,976
New +$8.4M
OTLK icon
104
Outlook Therapeutics
OTLK
$187M
$8.53M 0.11%
+714,285
New +$5.78M
PATH icon
105
UiPath
PATH
$7.2B
$8.45M 0.11%
372,739
+136,739
+58% +$3.2M
MURA
106
DELISTED
Mural Oncology
MURA
$8.11M 0.11%
1,658,000
ASO icon
107
Academy Sports + Outdoors
ASO
$2.98B
$8.04M 0.11%
119,048
-39,620
-25% -$2.67M
RVTY icon
108
Revvity
RVTY
$12.6B
$7.88M 0.1%
+75,000
New +$7.98M
TSM icon
109
TSMC
TSM
$2.17T
$7.62M 0.1%
56,000
-8,000
-13% -$994K
INSP icon
110
Inspire Medical Systems
INSP
$1.74B
$7.25M 0.1%
33,754
-2,768
-8% -$543K
CTLT
111
DELISTED
CATALENT, INC.
CTLT
$7.07M 0.09%
+125,260
New +$6.78M
ALGS icon
112
Aligos Therapeutics
ALGS
$31.9M
$6.76M 0.09%
275,736
+2,381
+0.9% +$47.4K
JACK icon
113
Jack in the Box
JACK
$336M
$6.51M 0.09%
+95,000
New +$7.15M
GB
114
DELISTED
Global Blue Group Holding
GB
$6.36M 0.08%
1,214,475
WST icon
115
West Pharmaceutical
WST
$24.4B
$6.32M 0.08%
+15,977
New +$5.91M
LEN icon
116
Lennar Class A
LEN
$20.5B
$6.19M 0.08%
+37,188
New +$5.59M
CLSD
117
DELISTED
Clearside Biomedical
CLSD
$6.05M 0.08%
+263,733
New +$5.68M
CHH icon
118
Choice Hotels
CHH
$4.96B
$6.04M 0.08%
47,796
+11,440
+31% +$1.37M
TXG icon
119
10x Genomics
TXG
$5.72B
$5.94M 0.08%
158,286
+66,286
+72% +$2.91M
ONON icon
120
On Holding
ONON
$12.5B
$5.65M 0.07%
159,709
-25,749
-14% -$787K
CKPT
121
DELISTED
Checkpoint Therapeutics
CKPT
$5.57M 0.07%
2,716,000
+290,000
+12% +$578K
VSXY
122
Victoria's Secret
VSXY
$7.41B
$5.52M 0.07%
+285,000
New +$6.99M
MTB icon
123
M&T Bank
MTB
$36.3B
$5.22M 0.07%
35,920
-4,080
-10% -$565K
ANGO icon
124
AngioDynamics
ANGO
$627M
$5.12M 0.07%
872,000
+72,000
+9% +$428K
ELDN icon
125
Eledon Pharmaceuticals
ELDN
$262M
$4.73M 0.06%
2,297,000
+108,000
+5% +$193K

Similar funds

Armistice Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Armistice Capital held 434 positions worth $7.54B, up 2.9% from $7.33B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Armistice Capital's Q1 2024 filing shows 139 new, 87 increased, 85 reduced and 95 closed positions. Its largest new stake was Cytokinetics: 1,525,688 shares worth $107M. The largest sale was Shockwave Medical, Inc. Common Stock, an estimated $88.4M.

By sector, the portfolio is most concentrated in Healthcare at 34% of assets, down from 35% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Armistice Capital's largest Q1 2024 buy was Cytokinetics: 1,525,688 shares worth $107M.
  • Armistice Capital added most to Incyte in Q1 2024, an estimated $117M increase.
  • Armistice Capital's biggest Q1 2024 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $88.4M.
  • Armistice Capital fully exited Jazz Pharmaceuticals in Q1 2024, selling an estimated $80.1M.
  • Armistice Capital's ten largest holdings make up 62% of its $7.54B portfolio in Q1 2024.
  • Armistice Capital opened 139 new positions and closed 95 in Q1 2024.
  • Armistice Capital's portfolio value rose 2.9% quarter-over-quarter to $7.54B.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.